@article{08d693eae52844b1b17930d107e3cc38,
title = "Rituximab in patients with primary CNS lymphoma (HOVON 105/ALLG NHL 24): a randomised, open-label, phase 3 intergroup study",
keywords = "NERVOUS-SYSTEM LYMPHOMA, WHOLE-BRAIN RADIOTHERAPY, HIGH-DOSE METHOTREXATE, ELDERLY-PATIENTS, IMPROVED SURVIVAL, CHEMOTHERAPY, IMMUNOCHEMOTHERAPY, TEMOZOLOMIDE, PROCARBAZINE, CYTARABINE",
author = "Bromberg, {Jacoline E. C.} and Samar Issa and Katerina Bakunina and Minnema, {Monique C.} and Tatjana Seute and Marc Durian and Gavin Cull and Schouten, {Harry C.} and Stevens, {Wendy B. C.} and Zijlstra, {Josee M.} and Baars, {Joke W.} and Marcel Nijland and Mason, {Kylie D.} and Aart Beeker and {van den Bent}, Martini and Max Beijert and Michael Gonzales and {de Jong}, Daphne and Doorduijn, {Jeanette K.}",
year = "2019",
month = feb,
doi = "10.1016/S1470-2045(18)30747-2",
language = "English",
volume = "20",
pages = "216--228",
journal = "Lancet oncology",
issn = "1470-2045",
publisher = "Elsevier Science",
number = "2",
}